3SBio to pay $50 mln for China rights to two Taiwan's TLC products

Taiwan Liposome Co. Ltd. (TLC), a clinical-stage pharmaceutical company, and Chinese rival 3SBio Inc. have agreed to an exclusive alliance to commercialize in mainland China two liposomal products.

Under the terms of the deal, 3SBio will pay up to $50 million in upfront payments for China rights to commercialize two liposomal products developed by Taiwan Liposome and utilising TLC’s proprietary NanoX technology platform.

TLC and 3SBio intend to obtain regulatory approvals in mainland China where TLC will utilize its commercial-scale manufacturing capabilities to supply the two liposome products for 3SBio to commercialize in mainland China.

Moreso, the two companies will further collaborate in research and development of other novel liposomal products in the therapeutic areas of osteoarthritis, pain management, ophthalmology, and oncology.